title: Better risk assessment for individual substances.
authors.forename: Roland W
authors.initials: RW
authors.lastname: Freudenmann
authors.forename: Ninja
authors.initials: N
authors.lastname: Freudenmann
authors.forename: Bartosz
authors.initials: B
authors.lastname: Zurowski
authors.forename: Carlos
authors.initials: C
authors.lastname: Schönfeldt-Lecuona
authors.forename: Bernhard J
authors.initials: BJ
authors.lastname: Connemann
authors.forename: Maximilian
authors.initials: M
authors.lastname: Gahr
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000175:diagnosis* / Q000188:drug therapy*
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics